Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
about
Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the Antitumor Immune ResponseBreaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression.Immunotherapy for cancer in the central nervous system: Current and future directionsFueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitorsExploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer ImmunotherapyThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsDevelopment of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung CancerStrategies and Advancements in Harnessing the Immune System for Gastric Cancer ImmunotherapyThe programmed death-1 immune-suppressive pathway: barrier to antitumor immunityImmunotherapy advances for glioblastomaVaccines for TB: Lessons from the Past Translating into Future PotentialsNon-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial DesignTumor infiltrating lymphocytes in ovarian cancerTIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV InfectionCombination Approaches with Immune-Checkpoint Blockade in Cancer TherapyImmune checkpoint and inflammation as therapeutic targets in pancreatic carcinomaAdjuvants for peptide-based cancer vaccinesMolecular targeted therapy for the treatment of gastric cancerIs There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsUpdate on immune checkpoint inhibitors in gynecological cancersThe role of immune checkpoint inhibition in the treatment of ovarian cancerHijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst FacetTherapeutic cancer vaccines and combination immunotherapies involving vaccinationMinireview: Regulatory T Cells and Ovarian Cancer.Advances in tumor screening, imaging, and avatar technologies for high-grade serous ovarian cancer.Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Immunotherapy for recurrent ovarian cancer: a further piece of the puzzle or a striking strategy?Reciprocal relationship of T regulatory cells and monocytic myeloid-derived suppressor cells in LP-BM5 murine retrovirus-induced immunodeficiencyOncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1Rational combinations of immunotherapeutics that target discrete pathways.Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy.Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical modelIntratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer.The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Single vs. combination immunotherapeutic strategies for glioma.Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis.A review of the application of inflammatory biomarkers in epidemiologic cancer research.
P2860
Q26744527-4F1B61FB-9E6A-4107-9A63-A1E37CE6E8F7Q26744624-54CDD7FF-B77D-4342-8768-5AD6029E6573Q26750765-52FD05EF-9A6F-4173-BD4F-4FC41A7B7A42Q26778793-D8CDAE14-4D4E-4B02-B581-DC1AEFCE1F5EQ26779184-6E07D6CC-A78E-4A53-9749-9F673E70E071Q26797478-3F076683-7945-46F5-B0E8-04E9CD8081CDQ26798047-DC97E883-013B-462F-B5C3-C17577B83B82Q26823515-25B3CA49-191E-4AB3-B491-2A362F557806Q26829847-D33581FA-843A-48CF-97FA-488A5255A3C0Q26866513-F0D85D07-583F-4C38-9325-674632EF8585Q26996673-6EA03BAE-8C85-43E2-89B3-388F88EBF5E3Q27003440-4C6D13D6-B263-4131-BA38-E1D1D5F040CFQ27021878-FC577E30-BC6A-48EB-BED3-0CCF1FFE9B6DQ27316403-337D5A1C-D786-4E4A-A20C-775F49314C38Q28066199-EA70B837-727B-42B8-A4C8-059847487A7EQ28069864-EFC38DB0-9D73-450D-8072-E6F4DCA66C31Q28072236-25051F4A-24F0-4492-A284-AF6718CBC9ABQ28072433-E4443ED3-87CA-4157-A5D1-ACCAACBA14C6Q28072532-7EA8F0CE-D520-4AD1-A0E2-C1505C5EE6DCQ28076497-E6BB04FE-CE3B-41EC-959D-2C8B4CF4EE8FQ28077924-C8866B54-8491-4D27-98E1-8FA7D42FD372Q28079816-E85276D7-B60D-4889-8904-B4D1596BED20Q28397609-BC9DAD99-080E-494E-BC9E-952C1BFDCD6DQ30244214-B8038587-E9BD-405B-852C-49F2D2F81AC3Q30423597-C4923E40-7B89-4A9D-A90F-304E47F9A4E8Q30846001-B382A05F-BD22-42A3-AC2A-61C06087D2B0Q33357295-8DEF549E-A1A0-4F03-ABF2-BBD4D4BE5E96Q33573202-0AFC3B2B-8FB3-433E-A1E1-6C37ECDFA3EEQ33579883-CD16A9AE-A8DF-4429-B1D6-E44C78F5BD8CQ33606144-396AA5A9-D816-4D67-9C40-4FFDFC28C107Q33606150-D87DB3EF-A596-476D-B624-6A2176E9A72BQ33633839-79A1264C-A437-48C8-BE00-02B3504A0D0BQ33658400-EE369BE7-1A00-476E-8A41-30BC19E6FBEFQ33728672-7C875155-AF70-4A21-8DFA-A18B1EE3E3EFQ33729278-00F406DA-E737-4C09-A6A3-9AB68B97DADAQ33736218-C959CBA6-062F-4C22-8966-11E4216889C4Q33746041-F823CA55-B932-4055-BFC5-0C81868FC2E6Q33779401-F4F43246-B78E-43E5-AE96-72531664F2DCQ33788235-DFCA59B4-F658-426B-B5AC-7A49D14D70D4Q34135803-8C142860-A8C1-42D6-B324-45D9A450539F
P2860
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Dual blockade of PD-1 and CTLA ...... rejection function in tumors.
@en
type
label
Dual blockade of PD-1 and CTLA ...... rejection function in tumors.
@en
prefLabel
Dual blockade of PD-1 and CTLA ...... rejection function in tumors.
@en
P2093
P2860
P1433
P1476
Dual blockade of PD-1 and CTLA ...... l rejection function in tumors
@en
P2093
Gordon J Freeman
Jaikumar Duraiswamy
Karen M Kaluza
P2860
P304
P356
10.1158/0008-5472.CAN-12-4100
P407
P577
2013-04-30T00:00:00Z